Tokyo, Japan

Yoshihito Kanzawa

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yoshihito Kanzawa

Introduction

Yoshihito Kanzawa is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for therapeutic applications. His work has implications for the treatment of glaucoma, showcasing his commitment to advancing medical science.

Latest Patents

Kanzawa holds a patent for a sulfonamide compound, specifically titled (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride. This compound is characterized by its crystal form, which exhibits major peaks in a powder X-ray diffraction spectrum at specific angles. The compound has demonstrated excellent properties as an active ingredient in medications aimed at the prophylactic and therapeutic treatment of glaucoma and similar conditions. He has 1 patent to his name.

Career Highlights

Yoshihito Kanzawa is currently employed at Asahi Kasei Pharma Corporation, where he continues to innovate and contribute to pharmaceutical research. His work at the company has positioned him as a key figure in the development of new therapeutic agents.

Collaborations

Kanzawa has collaborated with notable colleagues, including Hitoshi Kida and Koki Matsubara. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Yoshihito Kanzawa's contributions to medicinal chemistry and his innovative patent for a sulfonamide compound highlight his role as a significant inventor in the pharmaceutical industry. His work continues to impact the treatment of glaucoma, demonstrating the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…